Prasinezumab (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names NEOD002, PRX-002, RG-7935, RO-7046015) is an anti-α-synuclein drug acting as a monoclonal antibody against α-synuclein which is under development for the treatment of Parkinson's disease.[1][2][3][4] No significant effect on disease progression was seen in a 52-week phase 2clinical trial.[2] In any case, the trial was extended and development of the drug continues.[2] There have been concerns about research misconduct and data fabrication relevant to prasinezumab.[5] As of May 2024, prasinezumab is in phase 2 clinical trials for Parkinson's disease.[1] It is under development by Prothena Biosciences and Roche.[1]
